• Issue

    The Prostate: Volume 79, Issue 11

    1197-1359
    August 1, 2019
Previous Issue|Next Issue
Export Citation(s)Download PDF(s)

ISSUE INFORMATION

Free Access

Issue Information

  • Page: 1197
  • First Published: 28 June 2019

ORIGINAL ARTICLES

HnRNPM is a potential mediator of YY1 which promotes EMT in prostate cancer cells

Tong Yang,  Zesheng An,  Changwen Zhang,  Zhen Wang,  Xiaoming Wang,  Yan Liu,  E Du,  Ranlu Liu,  Zhihong Zhang,  Yong Xu, 
  • Pages: 1199-1210
  • First Published: 28 June 2019

Testosterone levels and androgen receptor copy number variations in castration-resistant prostate cancer treated with abiraterone or enzalutamide

Cristian Lolli,  Delia De Lisi,  Vincenza Conteduca,  Giorgia Gurioli,  Emanuela Scarpi,  Giuseppe Schepisi,  Giorgia Ravaglia,  Cecilia Menna,  Alberto Farolfi,  Amelia Altavilla,  Salvatore Luca Burgio,  Giuseppe Tonini,  Daniele Santini,  Ugo De Giorgi, 
  • Pages: 1211-1220
  • First Published: 28 June 2019

Outcome of Botulinum Toxin-A intraprostatic injection for benign prostatic hyperplasia induced lower urinary tract symptoms: A prospective multicenter study

Ayman S. Moussa,  Ahmed M. Ragheb,  Ahmed M. Abdelbary,  Rabie M. Ibrahim,  Mahmoud S. El Adawy,  Ahmad Aref,  Ahmed Assem,  Hany Elfayoumy,  Faysal Elzawy, 
  • Pages: 1221-1225
  • First Published: 12 June 2019

E-cadherin is downregulated in benign prostatic hyperplasia and required for tight junction formation and permeability barrier in the prostatic epithelial cell monolayer

Feng Li,  Laura E. Pascal,  Donna B. Stolz,  Ke Wang,  Yibin Zhou,  Wei Chen,  Yadong Xu,  Yule Chen,  Rajiv Dhir,  Anil V. Parwani,  Joel B. Nelson,  Donald B. DeFranco,  Naoki Yoshimura,  Goundappa K. Balasubramani,  Jeffrey R. Gingrich,  Jodi K. Maranchie,  Bruce L. Jacobs,  Benjamin J. Davies,  Ronald L. Hrebinko,  Joel D. Bigley,  Dawn McBride,  Peng Guo,  Dalin He,  Zhou Wang, 
  • Pages: 1226-1237
  • First Published: 18 June 2019

Heat injured stromal cells-derived exosomal EGFR enhances prostatic wound healing after thulium laser resection through EMT and NF-κB signaling

Fei Shi,  Zheng Deng,  Zheng Zhou,  Bo Jiang,  Chen-Yi Jiang,  Rui-Zhe Zhao,  Feng Sun,  Di Cui,  Meng-Hao Sun,  Qian Sun,  Xing-Jie Wang,  Qi Wu,  Shu-Jie Xia,  Bang-Min Han, 
  • Pages: 1238-1255
  • First Published: 24 May 2019

Distinct expression patterns of SULT2B1b in human prostate epithelium

Jiang Yang,  Meaghan M. Broman,  Paula O. Cooper,  Nadia A. Lanman,  Douglas W. Strand,  Colm Morrissey,  Timothy L. Ratliff, 
  • Pages: 1256-1266
  • First Published: 18 June 2019

PTEN loss in prostatic adenocarcinoma correlates with specific adverse histologic features (intraductal carcinoma, cribriform Gleason pattern 4 and stromogenic carcinoma)

Rajal B. Shah MD,  Karen T. Shore,  Jiyoon Yoon MD,  Savvas Mendrinos MD,  Jesse K. McKenney MD,  Wei Tian MD, 
  • Pages: 1267-1273
  • First Published: 21 May 2019
Open Access

Comparative analysis of p16 expression among African American and European American prostate cancer patients

Myra Wong MD,  Yaeli Bierman MD,  Curtis Pettaway MD,  Rick Kittles PhD,  Martha Mims MD PhD,  Jeffrey Jones MD,  Michael Ittmann MD PhD, 
  • Pages: 1274-1283
  • First Published: 21 May 2019

Triptonide acts as a novel antiprostate cancer agent mainly through inhibition of mTOR signaling pathway

Fulu Dong PhD,  Ping Yang PhD,  Rui Wang BS,  Wenxing Sun PhD,  Yonghui Zhang PhD,  Aiting Wang BS,  Miaomiao Chen MA,  Lu Chen BS,  Chong Zhang PhD,  Ming Jiang MD, PhD, 
  • Pages: 1284-1293
  • First Published: 18 June 2019

CUL4B regulates cancer stem-like traits of prostate cancer cells by targeting BMI1 via miR200b/c

Meng Jiao MD, MS,  Mei Qi MD, PhD,  Facai Zhang MD, MS,  Jing Hu MD, PhD,  Tingting Feng MD, MS,  Mingfeng Zhao MD, MS,  Xinjun Li MD, MS,  Hui Liu MD, MS,  Wei Teng MS,  Jing Zhang MS,  Zhiyan Liu MD, PhD,  Lili Zhang MD, MS,  Zhen Wu MD, MS,  Bo Han MD, PhD, 
  • Pages: 1294-1303
  • First Published: 21 May 2019

Targeting POH1 inhibits prostate cancer cell growth and enhances the suppressive efficacy of androgen deprivation and docetaxel

Wandong Yu,  Junhong Li MD,  Qiang Wang,  Boshi Wang,  Li Zhang,  Yun Liu,  Ming Tang,  Guiqing Xu,  Zhaojuan Yang,  Xilong Wang,  Jun Zhang,  Yongzhong Liu,  Guowei Shi MD, 
  • Pages: 1304-1315
  • First Published: 18 June 2019

Inflammation-associated pathologies in a case of prostate schistosomiasis: Implications for a causal role in prostate carcinogenesis

Lauren B. Peiffer,  Sarah L. Poynton,  Sarah E. Ernst,  Jessica L. Hicks,  Angelo M. De Marzo,  Karen S. Sfanos, 
  • Pages: 1316-1325
  • First Published: 18 June 2019

Establishing a cryopreservation protocol for patient-derived xenografts of prostate cancer

Laura H. Porter PhD,  Mitchell G. Lawrence PhD,  Hong Wang,  Ashlee K Clark PhD,  Andrew Bakshi MSc,  Daisuke Obinata MD PhD,  David Goode PhD,  Melissa Papargiris PhD,  MURAL,  David Clouston MBBS PhD FRACP,  Andrew Ryan MBBS FRCPA,  Sam Norden MBBS FRCPA,  Eva Corey PhD,  Peter S. Nelson MD,  John T. Isaacs PhD,  Jeremy Grummet MBBS MS FRACS,  John Kourambas MBBS FRACS,  Shahneen Sandhu MBBS MD FRACP,  Declan G. Murphy MB BCH BaO FRACS FRCS,  David Pook MBBS FRACP MD,  Mark Frydenberg MBBS FRACS,  Renea A. Taylor PhD,  Gail P. Risbridger PhD, 
  • Pages: 1326-1337
  • First Published: 18 June 2019

Circulating inflammation markers and prostate cancer

Henrik Ugge MD, PhD,  Mary K. Downer PhD,  Jessica Carlsson PhD,  Michaela Bowden PhD,  Sabina Davidsson PhD,  Lorelei A. Mucci ScD,  Katja Fall MD, PhD,  Sven-Olof Andersson MD, PhD,  Ove Andrén MD, PhD, 
  • Pages: 1338-1346
  • First Published: 18 June 2019
Open Access

Targeting prosurvival BCL2 signaling through Akt blockade sensitizes castration-resistant prostate cancer cells to enzalutamide

Amanda B. Pilling,  Clara Hwang, 
  • Pages: 1347-1359
  • First Published: 22 June 2019